DATES: Written proposals must be received at the above address by 5:00 p.m. on March 17, 1996.

SUPPLEMENTARY INFORMATION: The NCI is seeking a pharmaceutical or biotechnology company which, after obtaining a license in accordance with the requirements of the regulations governing the transfer of Government-developed rights, (37 CFR part 404), can purify a recombinant CR–1 protein (for which patents are pending or have been issued) and utilize this purified recombinant CR–1 protein as an immunogen to generate a panel of mouse monoclonal antibodies. The immunoreactive CR–1 protein has been detected by immunoperoxidase staining using a rabbit anti-peptide polyclonal CR–1 antibody in a majority of human colon cancers, breast cancers, gastric cancers, and pancreatic cancers. Little or no staining was detected in surrounding, noninvolved colon, breast or gastric epithelial cells. In addition, a majority of premalignant colonic adenomas, breast ductal carcinomas *in situ* and gastric intestinal metaplasia express immunoreactive CR–1.

A recombinant CR–1 protein has been generated using a baculovirus expression vector in Sf-9 insect cells and a partially purified protein obtained. This protein as well as synthetic, refolded peptides that correspond to the EGF-like domain in CR–1 are mitogenic for human breast cancer cells and can modulate milk protein expression, yet fail to bind to the EGF receptor or other type I receptor tyrosine kinases. Expression of CR–1 antisense mRNA using a recombinant, replication defective retroviral expression vector in colon cancer cells that expresses CR–1 inhibits the growth of these cells *in vivo* in nude mice. In order to utilize diagnostic and therapeutic potentials of CR–1, it will be necessary to purify a significant amount of the recombinant CR–1 protein to more fully define its biological properties and to identify the receptor through which it functions. In addition, mouse monoclonal antibodies against the purified CR–1 recombinant protein will expedite screening studies for CR–1 expression in other human premalignant lesions and cancers and should exhibit more specificity and sensitivity for the detection of CR–1 in tissues by immunocytochemistry (ICC) or in tissue extracts or serum samples by ELISA.

The United States Public Health Service owns the following issued patents which may be relevant to the subject technology:

1. United States Patent No. 5,264,557, issued November 23, 1993, ''Human CRIPTO-Related Gene.''

2. United States Patent No. 5,256,643, issued October 26, 1993, ''Cloned Human CRIPTO Gene and Applications Thereof.''

Questions regarding licensing should be directed to Joseph Hemby, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, #325, Rockville, MD 20852–3804, telephone (301) 496–7056.

The role of the National Cancer Institute, Division of Basic Sciences, includes:

1. NCI will provide vectors that encode CR–1 and can be used to produce CR–1 in *E. coli* and in Sf-9 insect cells.

2. NCI will provide a rabbit polyclonal anti-CR–1 antibody for monitoring CR–1 recovery during the purification from the yeast conditioned medium.

3. NCI will assay the purified recombinant CR–1 protein for bioactivity.

4. NCI will screen anti-CR–1 monoclonal antibodies for reactivity by Western blot analysis against native CR–1 protein from CR–1 positive human embryonal carcinoma or colon carcinoma cells.

The role of the successful collaborator will include:

1. Purify to homogeneity 30–50 milligrams of CR–1 from *E. coli* or Sf-9 insect cell conditioned medium.

2. Provide the purified recombinant CR–1 protein.

3. Utilize the purified recombinant CR–1 protein to generate mouse anti-CR–1 monoclonal antibodies.

4. Screen anti-CR–1 monoclonal antibodies for specificity, reactivity, and sensitivity towards the recombinant CR–1 protein.

5. Ascertain whether monoclonal anti-CR–1 antibodies can detect nature CR–1 protein in CR–1 positive human colorectal or embryonal carcinoma cells by radioimmunoprecipitation analysis and by ELISA.

6. Determine whether anti-CR–1 antibodies can be used for ICC on formalin-fixed, paraffin embedded tissues known for CR–1 expression.

7. Provide funds to support a postdoctoral fellow and associated expenses.

Criteria for choosing the collaborator will include:

1. Experience in producing and purifying recombinant proteins, particularly growth factors or cytokines.

2. Experience in generating and screening monoclonal antibodies.

3. Willingness to cooperate with the NCI in the collection and evaluation of data.

4. Willingness to cost share in laboratory expenses.

5. And agreement to be bound by the DHHS rules involving the use of human and animal subjects and human tissues.

6. Provisions for equitable distribution of patent rights to any inventions. Generally, the rights of ownership are retained by the organization(s) which is/are the employer(s) of the inventor. For inventions made solely by the collaborator's employees, there shall be a grant to the Government of a nonexclusive, nontransferable, irrevocable, paid up license to practice the invention or have the invention practiced throughout the world by or on behalf of the Government for research or other Government purposes. For inventions not made solely by the collaborator's employees, there shall be a grant to the collaborator of an option to elect an exclusive or nonexclusive commercialization license.

Dated: December 9, 1996.

Thomas Mays,

Director, Office of Technology Development, National Cancer Institute, National Institutes of Health.

[FR Doc. 97–1004 Filed 1–14–97; 8:45 am]

BILLING CODE 4140–01–M

National Institute on Drug Abuse; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute on Drug Abuse (NIDA) Initial Review Group and Special Emphasis Panel meetings.

Purpose/Agenda: To review and evaluate grant applications.

Name of Committee: Human Development Research Subcommittee.

Date: February 11–12, 1997.

Time: 8:30 a.m.

Place: Double Tree Hotel, 1750 Rockville Pike, Rockville, MD 20852.

Contact Person: Kesinee Nimit, M.D., Scientific Review Administrator, Office of Extramural Program Review, National Institute on Drug Abuse, 5600 Fishers Lane, Room 10–22, Telephone (301) 443–9042.

Name of Committee: Neuropharmacology Research Subcommittee.

Date: February 11–12, 1997.

Time: 8:30 a.m.

Place: Hyatt Regency Bethesda, One Bethesda Metro Center, Bethesda, MD 20814.

Contact Person: Syed Husain, Ph.D, Scientific Review, Administrator, Office of Extramural Program Review, National Institute on Drug Abuse, 5600 Fishers Lane, Room 10–22, Telephone (301) 443–2620.

Name of Committee: Basic Behavioral Science Research Subcommittee.
Date: February 11–13, 1997.
Time: 8:30 a.m.
Place: Sheraton Washington Hotel, 2660 Woodley Road at Connecticut, N.W., Washington, DC 20008.
Contact Person: William C. Grace, Ph.D., Scientific Review Administrator, Office of Extramural Program Review, National Institute on Drug Abuse, 5600 Fishers Lane, Room 10–22, Telephone (301) 443–9042.

Name of Committee: Epidemiology and Prevention Research Subcommittee.
Date: February 11–13, 1997.
Time: 8:30 a.m.
Place: Double Tree Hotel, 1750 Rockville Pike, Rockville, MD 20852.
Contact Person: Raquel Crider, Ph.D., Scientific Review Administrator, Office of Extramural Program Review, National Institute on Drug Abuse, 5600 Fishers Lane, Room 10–22, Telephone (301) 443–9042.

Name of Committee: Molecular, Cellular and Chemical Neurobiology Research Subcommittee.
Date: February 12–14, 1997.
Time: 8:30 a.m.
Place: Ritz-Carlton Hotel at Pentagon City, 1250 South Hayes Street, Arlington, VA 22202.
Contact Person: Rita Liu, Ph.D., Scientific Review Administrator, Office of Extramural Program Review, National Institute on Drug Abuse, 5600 Fishers Lane, Room 10–22, Telephone (301) 443–2620.

Name of Committee: NIDA Special Emphasis Panel.
Date: February 13, 1997.
Time: 2:00 p.m.
Place: Sheraton Washington Hotel, 2660 Woodley Road at Connecticut, N.W., Washington, DC 20008.
Contact Person: Khursheed Asghar, Ph.D., Scientific Review Administrator, Office of Extramural Program Review, National Institute on Drug Abuse, 5600 Fishers Lane, Room 10–42, Telephone (301) 443–2620.

Name of Committee: Neurophysiology and Neuroanatomy Research Subcommittee.
Date: February 18–20, 1997.
Time: 8:30 a.m.
Place: Double Tree Hotel, 1750 Rockville Pike, Rockville, MD 20852.
Contact Person: Gamil Debbas, Ph.D., Scientific Review Administrator, Office of Extramural Program Review, National Institute on Drug Abuse, 5600 Fishers Lane, Room 10–22, Telephone (301) 443–2620.

The meetings will be closed in accordance with provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. The applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers: 93.277, Drug Abuse Research Scientist Development and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse Research Programs.)

Dated: January 10, 1997.

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 97–997 Filed 1–14–97; 8:45 am]

BILLING CODE 4140–01–M

National Institute on Drug Abuse; Notice of Meeting

Pursuant to Public Law 92–463, notice is hereby given of the meeting of the National Advisory Council on Drug Abuse, National Institute on Drug Abuse (NIDA) on February 4–5, 1997, at the National Institutes of Health, Building 31, 9000 Rockville Pike, Bethesda, MD 20892.

On February 4, from 9 a.m. to 4 p.m., the meeting will be held in Conference Rooms 9 and 10. In accordance with provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. and sec. 10(d) of Public Law 92–463, this portion of the meeting will be closed to the public for the review, discussion, and evaluation of grant applications. These applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

On February 5, from 9 a.m. to 5 p.m., the meeting will be held in Conference Room 6. This portion of the meeting will be open to the public for announcements and reports of administrative, legislative, and program developments in the drug abuse field. Attendance by the public will be limited to space available.

A summary of the meeting and a roster of committee members may be obtained from Ms. Camilla L. Holland, NIDA Committee Management Officer, National Institutes of Health, Parklawn Building, Room 10–42, 5600 Fishers Lane, Rockville, Maryland 20857 (301/443–2755).

Substantive program information may be obtained from Ms. Eleanor C. Friedenberg, Room 10–42, Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857, (301/443/2755).

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Ms. Eleanor C. Friedenberg in advance of the meeting.

(Catalog of Federal Domestic Assistance Program Numbers: 93.277, Drug Abuse Research Scientist Development and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse Research Programs.)

Dated: January 10, 1997.

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 97–998 Filed 1–14–97; 8:45 am]

BILLING CODE 4140–01–M

National Institute of Allergy and Infectious Diseases; Notice of Meeting: Allergy, Immunology, and Transplantation Research Committee

Pursuant to Public law 92–463, notice is hereby given of the meeting of the Allergy, Immunology, and Transplantation Research Committee on February 3–5, 1997, at the Belmont, 6555 Belmont Woods Road, Elkridge, Maryland.

The meeting will be open to the public from 8:30 to 9:30 a.m. on February 3, to discuss administrative details relating to committee business and program review, and for a report from the Director, Division of Extramural Activities, which will include a discussion of budgetary matters. Attendance by the public will be limited to space available.

In accordance with the provisions set forth in Sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. and sec. 10(d) of Public law 92–463, the meeting will be closed to the public for the review, discussion, and evaluation of individual grant applications and contract proposals from 9:30 a.m. until recess on February 3, from 9:30 a.m. until recess on February 4, and from 9:30 a.m. until adjournment on February 5. These applications, proposals, and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Ms. Claudia Goad, Committee Management Officer, National Institute of Allergy and Infectious Diseases, Solar Building, Room 3C26, National Institutes of Health, Bethesda, Maryland 20892, 301–496–7601, will provide a summary of the meeting and a roster of committee members upon request. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should